HB0034
Phase 3Small molecule
HB0034 is one of 39 small molecule programs targeting Adult. It is currently in Phase 3.
2
Indications
5
Total Trials
3
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
127 competitors in Adult
#DrugCompanyPhaseTrials
1Tebrazid
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase 3
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Mounjaro
Eli LillyPhase 2
Rifampicin
Boehringer IngelheimPhase 3
Myqorzo
CCytokinetics
Phase 3
Opzelura
DDizal Pharmaceuticals
Phase 2
NM8074
NNovelMed Therapeutics
Phase 2
HB0034
SShanghai Huaota Biopharmaceutical Co., Ltd.
Phase 3
EB-1020
OtsukaPhase 3
Augtyro
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Generalized Pustular Psoriasis3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HB0034. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details